These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36475814)

  • 21. Target volume definition in high-risk prostate cancer patients using sentinel node SPECT/CT and 18 F-choline PET/CT.
    Vees H; Steiner C; Dipasquale G; Chouiter A; Zilli T; Velazquez M; Namy S; Ratib O; Buchegger F; Miralbell R
    Radiat Oncol; 2012 Aug; 7():134. PubMed ID: 22873771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patterns of lymph node positivity on
    McClinton C; Niroumand M; Sood S; Shah V; Hill J; Dusing RW; Shen X
    Pract Radiat Oncol; 2017; 7(5):325-331. PubMed ID: 28377141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET.
    de Jong IJ; Pruim J; Elsinga PH; Vaalburg W; Mensink HJ
    J Nucl Med; 2003 Mar; 44(3):331-5. PubMed ID: 12620996
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic performance of 18F-fluciclovine PET/CT for regional lymph node metastases in patients with primary prostate cancer: a multicenter phase II clinical trial.
    Suzuki H; Jinnouchi S; Kaji Y; Kishida T; Kinoshita H; Yamaguchi S; Tobe T; Okamura T; Kawakita M; Furukawa J; Otaka A; Kakehi Y
    Jpn J Clin Oncol; 2019 Sep; 49(9):803-811. PubMed ID: 31095314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 18F-Fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent.
    Tilki D; Reich O; Graser A; Hacker M; Silchinger J; Becker AJ; Khoder W; Bartenstein P; Stief CG; Loidl W; Seitz M
    Eur Urol; 2013 May; 63(5):792-6. PubMed ID: 22902037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?
    Castellucci P; Fuccio C; Rubello D; Schiavina R; Santi I; Nanni C; Allegri V; Montini GC; Ambrosini V; Boschi S; Martorana G; Marzola MC; Fanti S
    Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):55-63. PubMed ID: 20848281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection rate of 18F-Choline positron emission tomography/computed tomography in patients with non-metastatic hormone sensitive and castrate resistant prostate cancer.
    Zattoni F; Artioli P; Burei M; Chiaravalloti A; Chierichetti F; Donner D; Panareo S; Rambaldi I; Schillaci O; Dal Moro F; Evangelista L
    Q J Nucl Med Mol Imaging; 2023 Jun; 67(2):167-173. PubMed ID: 34477346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
    BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stereotactic Body Radiation Therapy Salvage for Lymph Node Recurrent Prostate Cancer in the Era of PSMA PET Imaging.
    Hayek OE; Rais-Bahrami S; McDonald A; Galgano SJ
    Curr Urol Rep; 2023 Oct; 24(10):471-476. PubMed ID: 37395949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil.
    Kitajima K; Murphy RC; Nathan MA; Froemming AT; Hagen CE; Takahashi N; Kawashima A
    J Nucl Med; 2014 Feb; 55(2):223-32. PubMed ID: 24434294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of lymph node metastasis in patients with nodal prostate cancer relapse using (18)F/(11)C-choline positron emission tomography/computerized tomography.
    Jilg CA; Schultze-Seemann W; Drendel V; Vach W; Wieser G; Krauss T; Jandausch A; Hölz S; Henne K; Reske SN; Grosu AL; Weber WA; Rischke HC
    J Urol; 2014 Jul; 192(1):103-10. PubMed ID: 24518792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Utility of [11C]choline PET/CT in guiding lesion-targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: results from a pathologically validated series.
    Passoni NM; Suardi N; Abdollah F; Picchio M; Giovacchini G; Messa C; Freschi M; Montorsi F; Briganti A
    Urol Oncol; 2014 Jan; 32(1):38.e9-16. PubMed ID: 23769269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pattern of occult nodal relapse diagnosed with (18)F-fluoro-choline PET/CT in prostate cancer patients with biochemical failure after prostate-only radiotherapy.
    Lépinoy A; Cochet A; Cueff A; Cormier L; Martin E; Maingon P; Bosset JF; Brunotte F; Créhange G
    Radiother Oncol; 2014 Apr; 111(1):120-5. PubMed ID: 24780635
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment.
    Chen B; Bathala TK; Xu G; Teyateeti A; Chapin BF; Tang C; Tu SM; Macapinlac HA; Lu Y
    Clin Nucl Med; 2020 May; 45(5):349-355. PubMed ID: 31977495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First results of [11C]choline PET/CT-guided secondary lymph node surgery in patients with PSA failure and single lymph node recurrence after radical retropubic prostatectomy.
    Winter A; Uphoff J; Henke RP; Wawroschek F
    Urol Int; 2010; 84(4):418-23. PubMed ID: 20299773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toxicity and efficacy of salvage carbon 11-choline positron emission tomography/computed tomography-guided radiation therapy in patients with lymph node recurrence of prostate cancer.
    Fodor A; Berardi G; Fiorino C; Picchio M; Busnardo E; Kirienko M; Incerti E; Dell'Oca I; Cozzarini C; Mangili P; Pasetti M; Calandrino R; Gianolli L; Di Muzio NG
    BJU Int; 2017 Mar; 119(3):406-413. PubMed ID: 27104782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison between pelvic PSMA-PET/MR and whole-body PSMA-PET/CT for the initial evaluation of prostate cancer: a proof of concept study.
    Domachevsky L; Bernstine H; Goldberg N; Nidam M; Catalano OA; Groshar D
    Eur Radiol; 2020 Jan; 30(1):328-336. PubMed ID: 31332559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancer: A retrospective analysis.
    Evangelista L; Cimitan M; Zattoni F; Guttilla A; Zattoni F; Saladini G
    Scand J Urol; 2015; 49(5):345-53. PubMed ID: 25649494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial.
    Ceci F; Herrmann K; Castellucci P; Graziani T; Bluemel C; Schiavina R; Vollmer C; Droll S; Brunocilla E; Mazzarotto R; Buck AK; Fanti S
    Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2222-31. PubMed ID: 25182750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen (
    Huits TH; Luiting HB; van der Poel HG; Nandurkar R; Donswijk M; Schaake E; Vogel W; Roobol MJ; Wit E; Stricker P; Emmett L; van Leeuwen PJ
    BJU Int; 2020 Jun; 125(6):876-883. PubMed ID: 32181951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.